Abstract
Harvard researchers have shown that blocking activin A induces osteoblast formation, providing a strategy to counter bone loss in a variety of indications as well as a rationale for partners Acceleron Pharma and Celgene to develop their soluble activin receptor decoy for multiple myeloma–induced osteolysis.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
